Huadong Medicine stock: fair value
000963.SZThe fair value of Huadong Medicine under our model is $7.49, the price is 47% below.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $5.76 and expensive above $10.70 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $5.41 (cash-flow model) and $9.57 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $7.03, at 6.3% it would be $8.17.
Where the number comes from
Half from the cash-flow model, half from earnings times the industry P/E (32.5).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 2.3%. Discounted at 7.3% (floor: government bond yield 2.3% plus 5 percentage points, since beta 0.82 times the risk premium would give less); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $5.41 per share: free cash flow for the next ten years, each year discounted to today at 7.3%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 7.3%) |
|---|---|---|---|---|
| 2026 | $423.69M | extrapolated at 8.3% | 0.9319 | $394.83M |
| 2027 | $451.18M | extrapolated at 6.5% | 0.8684 | $391.81M |
| 2028 | $474.8M | extrapolated at 5.2% | 0.8092 | $384.23M |
| 2029 | $495.49M | extrapolated at 4.4% | 0.7541 | $373.66M |
| 2030 | $514.03M | extrapolated at 3.7% | 0.7027 | $361.23M |
| 2031 | $531.06M | extrapolated at 3.3% | 0.6549 | $347.78M |
| 2032 | $547.06M | extrapolated at 3.0% | 0.6103 | $333.85M |
| 2033 | $562.39M | extrapolated at 2.8% | 0.5687 | $319.82M |
| 2034 | $577.31M | extrapolated at 2.7% | 0.5300 | $305.95M |
| 2035 | $592.04M | extrapolated at 2.6% | 0.4939 | $292.38M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $3.51B |
| Terminal value: cash flow 2035 × (1 + 2.3%) / (7.3% − 2.3%) | $12.11B |
| Present value of terminal value (× 0.4939) | $5.98B |
| Equity value (sum plus present value of terminal value) | $9.49B |
| Shares (diluted) | 1.75B |
| Value per share (equity value divided by shares) | $5.41 |
| Earnings per share, last twelve months | $0.29 |
| × 32.5 (industry P/E) | $9.57 |
| Fair value (average of both parts) | $7.49 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 12 Dec 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.